Pharmacokinetics of the raltegravir/maraviroc/etravirine combination

Journal of Antimicrobial Chemotherapy

Volumn 66, Issue 8, 2011, Pages 1932-1934

  Calcagno, Andrea ^a   Nozza, Silvia ^b   Bonora, Stefano ^a   Castagna, Antonella ^b   de Requena, Daniel Gonzalez ^a   D'Avolio, Antonio ^a   Lazzarin, Adriano ^b   di Perri, Giovanni ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

NRTI sparing; PI sparing; Therapeutic drug monitoring

Indexed keywords

ETRAVIRINE; MARAVIROC; RALTEGRAVIR;

ADULT; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONCENTRATION RESPONSE; DRUG BLOOD LEVEL; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; MALE; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CYCLOHEXANES; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PYRIDAZINES; PYRROLIDINONES; SALVAGE THERAPY; TRIAZOLES;

EID: 79960460253     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkr219     Document Type: Letter

References (10)

1. Nozza S, Galli L, Bigoloni A et al. Durability and safety of a novel salvage therapy in R5-tropic HIV-infected patients: maraviroc, raltegravir, etravirine. J Acquir Immune Defic Syndr 2011; 56: e113-5.
2. Davis J, Scholler-Gyure M, Kakuda TN et al. An open randomised two period crossover study in 2 cohorts to investigate the effect of steady state TMC125 and the combination of TMC125/DRV/r on the steady state pharmacokinetics of oral maraviroc in healthy subjects. In: Abstracts of the Eleventh European AIDS Conference (EACS), Madrid, Spain, 2007. Abstract P3.4/02.
3. Anderson MS, Kakuda TN, Hanley W et al. Minimal pharmacokinetic interaction between the human immunodeficiency virus nonnucleoside reverse transcriptase inhibitor etravirine and the integrase inhibitor raltegravir in healthy subjects. Antimicrob Agents Chemother 2008; 52: 4228-32.
4. Menard A, Solas C, Mokthari S et al. Etravirine-raltegravir, a marked interaction in HIV-1-infected patients: about four cases. AIDS 2009; 23: 869-71.
5. Andrews E, Glue P, Fang J et al. Assessment of the pharmacokinetics of co-administered maraviroc and raltegravir. Br J Clin Pharmacol 2010; 69: 51-7.
6. D'Avolio A, Baietto L, Siccardi M et al. An HPLC-PDA method for the simultaneous quantification of the HIV integrase inhibitor raltegravir, the new nonnucleoside reverse transcriptase inhibitor etravirine, and 11 other antiretroviral agents in the plasma of HIV-infected patients. Ther Drug Monit 2008; 30: 662-9.
7. Boffito M, Winston A, Jackson A et al. Pharmacokinetics and antiretroviral response to darunavir/ritonavir and etravirine combination in patients with high-level viral resistance. AIDS 2007; 21: 1449-55.
8. Ter Heine R, Mulder JW, van Gorp EC et al. Intracellular and plasma steady-state pharmacokinetics of raltegravir, darunavir, etravirine and ritonavir in heavily pre-treated HIV-infected patients. Br J Clin Pharmacol 2010; 69: 475-83.
9. Baroncelli S, Villani P, Weimer LE et al. Raltegravir plasma concentrations in treatment-experienced patients receiving salvage regimens based on raltegravir with and without maraviroc coadministration. Ann Pharmacother 2010; 44: 838-43.
10. McFadyen L, Wade JR, Weatherley B et al. Maraviroc (MVC) exposure-efficacy relationship in treatment-experienced HIV-1-infected patients. In: Abstracts of the Eleventh European AIDS Conference (EACS), Madrid, Spain, 2007. Abstract P4.1/06.